Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement.

Area of Science:

• Rheumatology and Cardiology
• Immunology and Inflammation
• Connective Tissue Diseases

Background:

• Systemic sclerosis (SSc) is a severe connective tissue disease with high morbidity and mortality.
• Cardiac involvement is common in SSc, often asymptomatic, and a major cause of death.
• Myocardial fibrosis is a key feature, with pathogenesis involving vascular and inflammatory pathways.

Purpose of the Study:

• To review the role of interleukin-1 (IL-1) and inflammasome in SSc and cardiac inflammation.
• To explore the link between cellular metabolism and inflammasome activation in SSc.
• To discuss the potential of IL-1 inhibition as a therapeutic strategy for SSc-heart involvement.

Main Methods:

• Review of emerging evidence on IL-1 and inflammasome in SSc and cardiac inflammation.
• Analysis of the interplay between cellular metabolism and inflammasome activation.
• Discussion of preliminary experimental and clinical data supporting IL-1 inhibition.

Main Results:

• Interleukin-1 (IL-1) plays a central role in the inflammatory cascade leading to cardiac dysfunction in SSc.
• Inflammation-driven pathways are critical in the progression to myocardial fibrosis.
• Preliminary data suggest IL-1 inhibition is a viable therapeutic approach for SSc-related heart disease.

Conclusions:

• IL-1 and inflammasome activation are key players in SSc-associated heart inflammation and fibrosis.
• Targeting IL-1 offers a promising therapeutic strategy for managing cardiac complications in SSc.
• Further research into IL-1 inhibition is warranted for SSc patients with heart involvement.